Open AccessDESIGN, DEVELOPMENT AND EVALUATION OF DILTIAZEM HYDROCHLORIDE LOADED NANOSPONGES FOR ORAL DELIVERY
Author(s) -
B. NARASIMHA RAO,
K. RAVINDRA REDDY,
S. RAHATH FATHIMA,
P. PREETHI
Publication year - 2020
Publication title -
international journal of current pharmaceutical research
Language(s) - English
Resource type - Journals
ISSN - 0975-7066
DOI - 10.22159/ijcpr.2020v12i5.39784
Subject(s) - diltiazem hydrochloride , ethyl cellulose , cyclodextrin , chemistry , cellulose , scanning electron microscope , fourier transform infrared spectroscopy , drug delivery , chromatography , chemical engineering , polymer , organic chemistry , materials science , diltiazem , composite material , engineering , calcium
Objective: In the current investigation,nanosponges were set up by emulsion solvent diffusion technique utilizing ethyl cellulose and β-cyclodextrin as polymers.
Methods: Diltiazem hydrochloride is taken as model medication for considering different nanosponge formulations. The similarity of different formulation segments was set up by Fourier Transform Infra-Red (FTIR) spectroscopy. Molecular size, surface morphology, entrapment efficiency and drug content of nanosponges were analyzed. Shape and surface morphology of the nanosponges were inspected utilizing scanning electron microscopy.
Results: Molecule size of formulated nanosponges was seen in the scope of 186 to 476 nm. Scanning electron microscopy uncovered the permeable, round nature of the nanosponges. The drug content of nanosponges for ethyl cellulose containing formulations was seen as in the scope of 62.25 to 85.11% and for the β-cyclodextrin containing details were seen as in the scope of 65.18-89.67%. The percentage entrapment effectiveness of nanosponges for ethyl cellulose containing formulations were seen as in the scope of 54.18 to 79.49% and for the β-cyclodextrin containing details were seen as in the scope of 58.21-83.45%. In vitro drugreleasefindings demonstrated that at 12 h ethyl cellulose containing formulations discharged the drug in the scope of 57.27-89.09% and for the β-cyclodextrin containing formulations discharged in the scope of 73.94-93.26%.
Conclusion: Sustained drugreleasefrom formulations is supported if there is an occurrence of ethyl cellulose in the formulations rather with plans containing β-cyclodextrin.